268,000.00
+19,400.00
(7.80%)
Jun 20 - Close
TYO
data delayed by 20 mins -
Disclaimer
Currency in JPY
| Range | 258,100.00 - 279,600.00 |
| 52 week | 35,650.00 - 563,000.00 |
| Open | 275,800.00 |
| Vol / Avg. | 24,399.00/21,621.00 |
| Mkt cap | 87.18B |
| P/E | - |
| Div/yield | - |
| EPS | -1,909.72 |
| Shares | 325,307.00 |
| Beta | - |
| Inst. own | - |
Events
May 14, 2013
Full Year 2013 NanoCarrier Co Ltd Earnings Presentation (Japanese)
May 13, 2013
Full Year 2013 NanoCarrier Co Ltd Earnings Release
|
|
Key stats and ratios
| Q1 (Mar '13) | 2013 | |
| Net profit margin | -74.26% | -129.61% |
| Operating margin | -125.12% | -154.41% |
| EBITD margin | - | -139.10% |
| Return on average assets | -9.53% | -10.45% |
| Return on average equity | -13.15% | -15.48% |
| Employees | 29 | - |
| Carbon Disclosure Rating | - | - |
Address
Kashiwanoha 5-4-19
KASHIWA-SHI, CHB 277-0882
Japan
+81-47-1696550 (Phone)
+81-47-1696551 (Fax)
KASHIWA-SHI, CHB 277-0882
Japan
+81-47-1696550 (Phone)
+81-47-1696551 (Fax)
Website links
External links
Discussion Group - Google Finance
Advertisement
Description
NanoCarrier Co., Ltd. is a Japan-based biopharmaceutical products developer. The Company develops biopharmaceutical products focused on the medication of cancer and other intractable diseases. It is engaged in the research, development, manufacture, and sale of anti-cancer drugs based on micellar nanoparticle technology. The Company's product candidates include Paclitaxel Micelle for the treatment of stomach cancer, Nanoplatin for the treatment of pancreatic cancer, and DACH-Platin Micelle for the treatment of solid cancer.
Officers and directors
| Ichiro Nakatomi | President, Chief Executive Officer, Representative Director | |
| Takuma Nakatsuka | Chief Financial Officer, Director of Administration, Manager of President's Office, Director | |
| Yasuki Kato | Chief Study Officer, Board of Director | |
| Hiroyuki Hanada | Chief Business Officer, Board of Director | |
| Satoru Iino | Independent Director | |
| Atsushi Matsumura | Independent Director | |
| Akira Ohashi | Independent Director | |
| Teruo Okano Ph.D. | Independent Director |